Evidence map›Paper›PMID 29371653›Full record

ArticleNature neuroscience2018

Nuclear pores: the gate to neurodegeneration.

Nan Li, Clotilde Lagier-Tourenne

Abstract readComment
PubMed Publisher
In one paragraph

Article in Nature neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. SIGMAR1 Confers Innate Resilience against Neurodegeneration.International journal of molecular sciences · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. X-linked dystonia-parkinsonism: over and above a repeat disorder.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2021
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Nan LiMassGeneral Institute for Neurodegenerative Disease (MIND), Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Clotilde Lagier-TourenneMassGeneral Institute for Neurodegenerative Disease (MIND), Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. clagier-tourenne@mgh.harvard.edu.ORCID 0000-0002-3058-8322

Funding

Using RNA signatures for therapy development in neurodegeneration due to C9orf72 expansionsR01NS087227 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LAGIER-TOURENNE, CLOTILDE · 2014 to 2018
$1.5M
NINDS NIH HHS R01 NS087227
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Nuclear EnvelopeNuclear PoreActive Transport, Cell NucleusAmyotrophic Lateral SclerosisDNA-Binding ProteinsHumansDNA-Binding Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.